Juno Therapeutics (NASDAQ: JUNO) is focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human T cells as therapeutics will drive one of the next important phases in medicine, the company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno Therapeutics has shown compelling evidence of tumor shrinkage in clinical trials using multiple cell-based product candidates to address refractory B-cell lymphomas and leukemias. Longer term, the company aims to develop its cell-based platform to include additional product candidates to address a broad range of cancers and human diseases.

On January 22, 2018, Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics (NASDAQ:JUNO) announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.